# Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

> **NCT03535272** · PHASE3 · TERMINATED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 482 (actual)

## Conditions studied

- Diarrhea Travelers
- Antibiotic Resistant Infection

## Interventions

- **DRUG:** Bismuth subsalicylate
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03535272
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-20
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 482 (ACTUAL)
- **Why stopped:** Unable to reach target sample size.
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535272, "Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03535272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*